(Q34778074)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Thalidomide as an anti-cancer agent (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

0 references

3

S V Rajkumar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

S Kumar

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

T E Witzig

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 April 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cellular and Molecular Medicine

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

160-174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

Thalidomide is an inhibitor of angiogenesis

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Clinical pharmacology of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Thalidomide and its analogues as cyclooxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Thalidomide treatment in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Thalidomide as an anti-angiogenic agent in relapsed gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

THALIDOMIDE AND CONGENITAL ABNORMALITIES

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2002.TB00184.X

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

12 December 2020

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

1 reference

12 December 2020

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

Phase II evaluation of thalidomide in patients with metastatic breast cancer

1 reference

12 December 2020

Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood

1 reference

12 December 2020

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

12 December 2020

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

1 reference

12 December 2020

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

1 reference

12 December 2020

Irinotecan and thalidomide in metastatic colorectal cancer

1 reference

12 December 2020

Thalidomide treatment of resistant or relapsed multiple myeloma patients

1 reference

12 December 2020

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

1 reference

12 December 2020

Treatment of Waldenstrom's macroglobulinemia with thalidomide

1 reference

12 December 2020

The treatment of advanced renal cell cancer with high-dose oral thalidomide

1 reference

12 December 2020

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

12 December 2020

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma

1 reference

12 December 2020

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

1 reference

12 December 2020

Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

Human teratogenesis: In vitro studies on thalidomide-inhibited chondrogenesis

1 reference

12 December 2020

Quantification of angiongenesis as an independent predictor of prognosis in invasive bladder carcinomas

1 reference

12 December 2020

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

12 December 2020

Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides

1 reference

12 December 2020

The effect of thalidomide on experimental tumors and metastases

1 reference

12 December 2020

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

12 December 2020

Neural crest defects. A neuroanatomic basis for classification of multiple malformations related to phocomelia

1 reference

12 December 2020

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

12 December 2020

Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre

1 reference

12 December 2020

Pharmacokinetics of thalidomide in an elderly prostate cancer population

1 reference

12 December 2020

Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies

1 reference

12 December 2020

10.1111/J.1582-4934.2002.TB00184.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12169202%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference